Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence – a systematic review and meta-analysis

Wallerstedt, Sven; Ek, Astrid Nilsson; Bagge, Roger Olofsson; Kovács, Anikó; Strandell, Annika; Linderholm, Barbro

doi:10.1007/s00228-020-02914-z

Cited by 2 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the included articles were narrative reviews [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ] (36%) and qualitative researches [ 33 , 34 , 35 , 36 , 37 , 38 , 39 ] (28%). As reported in Table 1 , six [ 24 , 25 , 27 , 34 , 40 , 41 ] out of 25 articles (24%) were classified in group 1, since they satisfied at least 75% of the quality criteria, while the majority—11 [ 26 , 31 , 33 , 35 , 37 , 38 , 39 , 42 , 43 , 44 , 45 ] out of 25 articles (44%)—were allocated in group 2, meeting between 55% and 74% of the quality criteria. Lastly, 8 [ 28 , 29 , 30 , 32 , 36 , 46 , 47 , 48 ] out of 25 studies (32%) were inserted in group 3, satisfying less than 55% of the quality criteria.…”

Section: Resultsmentioning

confidence: 99%

“…Eleven [ 24 , 28 , 30 , 32 , 33 , 34 , 35 , 41 , 43 , 45 , 46 ] out of twenty-five articles (44%) provided information on personalized medicine for the treatment of breast cancer. Results about key dimensions were: Molecular board (compositions and conditions for efficacy): the role, responsibilities and tasks of all members, in particular pathologists and surgeons [ 24 , 28 , 32 , 33 , 35 ] (45%); Evidence-based genetic testing: the benefits and clinical validity of -omics technologies, focusing on BRCA and Oncotype DX [ 24 , 30 , 32 , 34 , 35 , 41 , 43 , 45 , 46 ] (82%); Shared-clinical decision-making: a positive impact on the selection of targeted therapy and improvements in chemotherapy, endocrine, and chemo-endocrine therapy decisions [ 24 , 30 , 32 , 34 , 35 , 41 , 43 , 45 , 46 ] (82%). …”

Section: Resultsmentioning

confidence: 99%

“…Evidence-based genetic testing: the benefits and clinical validity of -omics technologies, focusing on BRCA and Oncotype DX [ 24 , 30 , 32 , 34 , 35 , 41 , 43 , 45 , 46 ] (82%);…”

Section: Resultsmentioning

confidence: 99%

“…Eleven [24,28,30,[32][33][34][35]41,43,45,46] out of twenty-five articles (44%) provided information on personalized medicine for the treatment of breast cancer. Results about key dimensions were:…”

Section: Personalized Medicine Key Dimensionsmentioning

confidence: 99%

“…Molecular board (compositions and conditions for efficacy): the role, responsibilities and tasks of all members, in particular pathologists and surgeons [24,28,32,33,35] (45%); • Evidence-based genetic testing: the benefits and clinical validity of -omics technologies, focusing on BRCA and Oncotype DX [24,30,32,34,35,41,43,45,46] (82%); • Shared-clinical decision-making: a positive impact on the selection of targeted therapy and improvements in chemotherapy, endocrine, and chemo-endocrine therapy decisions [24,30,32,34,35,41,43,45,46] (82%).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework

Belvis

Pellegrino

Castagna

et al. 2021

JPM

View full text Add to dashboard Cite

Breast Cancer (BC) is the leading cause of death due to cancer in women. Ensuring equitable, quality-assured and effective care has increased the complexity of BC management. This systematic review reports on the state-of-the art of available literature investigating the enactment of personalized treatment and patient-centered care models in BC clinical practice, building a framework for the delivery of personalized BC care within a Patient-Centered model. Databases were searched for articles (from the inception to December 2020) reporting on Patient-Centered or Personalized Medicine BC management models, assessing success factors or limits. Out of 1885 records, 25 studies were included in our analysis. The main success factors include clearly defined roles and responsibilities within a multi-professional collaboration, appropriate training programs and adequate communication strategies and adopting a universal genomic language to improve patients’ involvement in the decision-making process. Among detected barriers, delays in the use of genetic testing were linked to the lack of public reimbursement schemes and of clear indications in timing and appropriateness. Overall, both care approaches are complementary and necessary to effectively improve BC patient management. Our framework attempts to bridge the gap in assigning a central role played by shared decision-making, still scarcely investigated in literature.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Evidence-based genetic testing: the benefits and clinical validity of -omics technologies, focusing on BRCA and Oncotype DX [ 24 , 30 , 32 , 34 , 35 , 41 , 43 , 45 , 46 ] (82%);…”

Section: Resultsmentioning

confidence: 99%

Section: Personalized Medicine Key Dimensionsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework

Belvis

Pellegrino

Castagna

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy

et al. 2023

View full text Add to dashboard Cite

Background: Many women with early-stage breast cancer are predicted to be at sufficiently low risk for recurrence that they may forego chemotherapy. Nevertheless, some low-risk women will experience a local recurrence, and for them the risk of death increases significantly thereafter. The utility of initiating chemotherapy at the time of local recurrence has not been adequately addressed. The purpose of this study is to identify, in a hospital-based series of patients with early-stage breast cancer who were not treated with chemotherapy, those factors which predict death post local recurrence. Methods: We identified 135 women who were diagnosed with early-stage breast cancer (node-negative, <5 cm) and who did not receive chemotherapy at diagnosis and who developed a local recurrence. They were diagnosed between 1987 and 2000 and treated at Women’s College Hospital. For each patient, we abstracted information on the initial cancer (age at diagnosis, tumour size, tumour grade, ER status, PR status, HER2 status, lympho-vascular invasion, type of surgery, use of radiotherapy, tamoxifen and chemotherapy), the time from initial diagnosis to local recurrence and treatment at recurrence. The Kaplan–Meier method was used to estimate the ten-year actuarial risk of breast cancer death post recurrence. A Cox proportional hazards model was used to estimate multivariate hazard ratios for the various factors. Results: Among the 135 women in the cohort, the mean time from initial diagnosis to local recurrence was 7.8 years (range: 0.3 to 22.6 years). A total of 38 of the 135 women (28.1%) died of breast cancer a mean of 5.3 years after experiencing the local recurrence (range: 0.3 to 17 years). The ten-year breast cancer survival post local recurrence was 71% and the 15-year survival was 65%. In a multivariate analysis, it was found that factors that were significantly associated with death after local recurrence were (1) PR-negative status, (2) young age at diagnosis (<40 years) and (3) time to local recurrence less than 2 years. Nine percent of women received chemotherapy at the time of local recurrence. Conclusions: For breast cancer patients with a low baseline risk of mortality, the risk of death after an isolated local recurrence is substantial. Systemic treatment at the time of local recurrence needs further study.

show abstract

Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence – a systematic review and meta-analysis

Cited by 2 publications

References 55 publications

Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework

Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework

Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy

Contact Info

Product

Resources

About